Quest for the right Drug
פיפרצילין / טזובקטם - פרזניוס 4 גר'/0.5 גר' PIPERACILLIN /TAZOBACTAM - FRESENIUS 4 G/0.5 G (PIPERACILLIN AS SODIUM SALT, TAZOBACTAM AS SODIUM SALT)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-ורידי : I.V
צורת מינון:
אבקה להכנת תמיסה לאינפוזיה : POWDER FOR SOLUTION FOR INFUSION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The most commonly reported adverse reactions is diarrhoea (occurring in 1 patient out of 10) Among the most serious adverse reactions pseudo-membranous colitis and toxic epidermal necrolysis occur in 1 to 10 patients in 10,000. The frequencies for pancytopenia, anaphylactic shock and Stevens-Johnson syndrome cannot be estimated from the currently available data. In the following table, adverse reactions are listed by system organ class and MedDRA- preferred term. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. System Organ Very Common Uncommon Rare Frequency not known Class common (≥ 1/100 to (≥ 1/1,000 to < (≥ 1/10,000 to (cannot be estimated (≥ 1/10) < 1/10) 1/100) < 1/1,000) from available data) Infections and candida infection * pseudo- infestations membranous colitis Blood and thrombocytopenia, leukopenia Pancytopenia*, lymphatic anaemia* agranulocytos neutropenia, haemolytic system disorders is anaemia*, eosinophilia*, thrombocytosis* Immune system anaphylactoid reaction*, disorders anaphylactic reaction*, anaphylactoid shock*, anaphylactic shock*, hypersensitivity* Metabolism and hypokalaemia nutrition disorders Psychiatric insomnia delirium* disorders Nervous system headache seizure* disorders Vascular hypotension, disorders thrombophlebiti s, phlebitis, flushing Respiratory, epistaxis eosinophilic pneumonia thoracic and mediastinal disorders Gastrointestinal diarrhea abdominal pain, stomatitis disorders vomiting, nausea, constipation, dyspepsia Hepatobiliary Hepatitis*, jaundice, disorders Skin and rash, pruritus erythema toxic Stevens-Johnson subcutaneous multiforme*, epidermal syndrome*, dermatitis tissue disorders urticaria, rash necrolysis* exfoliative, drug maculopapular* reaction with eosinophilia and systemic symptoms (DRESS)*, acute generalised exanthematous pustulosis (AGEP)*, dermatitis bullous, purpura Musculoskeletal arthralgia, and connective myalgia tissue disorders Renal and renal failure, urinary tubulointerstitial disorders nephritis* General pyrexia, injection- chills disorders and site reaction administration site conditions Investigations alanine blood glucose bleeding time aminotransferase decreased, blood prolonged, gamma- increased, aspartate bilirubin glutamyltransferase aminotransferase increased, increased increased, protein prothrombin total decreased, time prolonged blood albumin decreased, Coombs direct test positive, blood creatinine increased, blood alkaline phosphatase increased, blood urea increased, activated partial thromboplastin time prolonged *ADR identified post marketing Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients. Beta -lactam antibiotics class effects Beta -lactam antibiotics, including piperacillin tazobactam, may lead to manifestations of encephalopathy and convulsions (see section 4.4) Reporting of suspected adverse reactions Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/ and emailed to the Registration Holder’s Patient Safety Unit at: drugsafety@neopharmgroup.com.
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף